Hindustan Bio Sciences Ltd.
Snapshot View

3.72 -0.19 ▼-4.9%

20 May 2022, 04:01:00 PM
Volume: 2,805

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website https://www.hindustanbiosciences.in/
Market Cap 3.81 Cr.
Enterprise Value(EV) 5.92 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) -1.01 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 1.14 Trailing Twelve Months Ending 2021-12
Price to Book Value 3.25 Calculated using Price: 3.72
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.03 Cr. 10,250,800 Shares
FaceValue 10
Company Profile

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.

The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).

Products

The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.

Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.

In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.86%
1 Week
+3.05%
1 Month
-12.68%
3 Month
-21.19%
6 Month
-3.63%
1 Year
-11.43%
2 Year
+238.18%
5 Year
+158.33%
10 Year
+116.28%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -7.71 -11.47 -19.21 -35.60 -10.74 -71.30 5.22 3.67 -52.96
Return on Capital Employed (%) -7.32 -10.57 -16.78 -30.17 -8.37 -49.03 2.68 2.40 -23.70
Return on Assets (%) -6.96 -10.03 -16.51 -30.15 -8.42 -47.82 2.37 1.45 -20.83

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 9 8 7 5 4 2 2 2 1 1
Non Curr. Liab. 0 1 1 0 1 1 2 2 1 1
Curr. Liab. 1 1 0 1 1 1 1 2 1 1
Minority Int.
Equity & Liab. 10 10 8 6 6 4 6 6 3 3
Non Curr. Assets 8 8 7 5 5 3 4 3 2 2
Curr. Assets 2 2 1 1 1 0 2 2 1 1
Misc. Exp. not W/O 0 0
Total Assets 10 10 8 6 6 4 6 6 3 3

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 4 2 1 1 1 1 4 2 1 1
Other Income 0 0
Total Income 4 2 1 1 1 1 4 2 1 1
Total Expenditure -5 -3 -2 -1 -1 -3 -3 -2 -2 -2
PBIDT -1 -1 -1 0 0 -2 0 0 -1 -1
Interest 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0
Exceptional Items -2
PAT -1 -1 -1 -2 0 -2 0 0 -1 -1
Adjusted EPS -1 -1 -1 -2 0 -2 0 0 -1 -1

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 0 0 0 -1 1 1
Cash Fr. Inv. 0 0 0 0
Cash Fr. Finan. 0 1 0 -1 0 0 2 -1 -1
Net Change 0 0 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 12.19 12.19 12.19 12.19 12.19 12.19 12.19 12.19 12.19
Public 87.81 87.81 87.81 87.81 87.81 87.81 87.81 87.81 87.81
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance report for 2021-22
Fri, 20 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Revised Annual Secretarial compliance report for 2021-22
Fri, 13 May 2022
Board Meeting Intimation for Intimation Of Board Meeting Held On 27Th May 2022
HINDUSTAN BIO SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve Intimation of Board Meeting held on 27th May 2022

Technical Scans View Details

Fri, 20 May 2022
High Delivery Percentage High Delivery Percentage
Close Crossing Last Month Low Close Crossing Last Month Low
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months
High Increase 2 Years High Increase 2 Years

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%